Research Progress of Sacubitril-Valsartan in the Treatment of Cardiovascular Diseases
Received:July 10, 2019  Revised:July 30, 2019
View Full Text  View/Add Comment  Download reader
Key words:Sacubitril-Valsartan; Neuroendocrine inhibitor; Angiotensin Receptor - Neprilysin Inhibitor; Cardiovascular diseases
Author NameAffiliationE-mail
ZHU Lin 南京医科大学第二附属医院心血管内科 
洪梅 (Department of Cardiology, The Second Affiliated Hospital of Nanjing Medical University, 
Hits: 152
Download times: 
      Despite significant advances in the treatment of cardiovascular disease, it remains a major public health problem worldwide and the morbidity and mortality are projected to increase. Therefore, exploring new drugs is a hot spot in the treatment of cardiovascular diseases now. Sacubitril-valsartan is a novel neuroendocrine inhibitor with a dual inhibition of angiotensin receptor and neprilysin, and it makes great progress in the management of cardiovascular diseases in the past decade. This paper reviews the researches of sacubitril-valsartan in the treatment of cardiovascular diseases.